OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
605957

Uchiyama Holdings Co Ltd

Healthcare Facilities & ServicesVerified

Uchiyama Holdings Co Ltd has a liquidity position that is currently medium, with a current ratio of 1.62, indicating the company can cover its short-term liabilities with its short-term assets. The company holds JPY 10,758,237,000 in cash and equivalents, but this is offset by long-term debt of JPY 13,637,708,000, resulting in a negative net cash position. This suggests the company may need to rely on operating cash flow or external financing to service its debt obligations. The company's profitability is underperforming relative to industry norms, with a return on equity (ROE) of -1.29% and a return on assets (ROA) of -0.51%. These negative returns indicate that the company is not generating sufficient returns to cover its cost of capital, which is a concern for investors. The operating loss of JPY 294,567,000 and net loss of JPY 158,982,000 further underscore the company's financial challenges. Uchiyama Holdings Co Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to sector-specific risks, such as regulatory changes or shifts in demand for biotechnology services. The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The operating cash flow of JPY 2,002,765,000 is a positive sign, but it is not sufficient to offset the net loss or the capital expenditure of JPY 896,404,000. The company's capital structure is heavily leveraged, with a debt-to-equity ratio of 1.1, which increases financial risk and may limit its ability to invest in growth opportunities. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position is a key flag, suggesting potential liquidity constraints. However, the low dilution risk implies that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders. The company's recent financial performance and capital structure suggest that it may need to manage its debt more effectively to improve its financial health. Recent events, including the company's financial performance and capital structure, have been disclosed in its latest financial statements. The company's operating cash flow and capital expenditure figures indicate that it is investing in its operations, but the net loss and negative ROE suggest that these investments are not yet generating returns. The company's management will need to address these issues to improve its financial performance and reduce its financial risk.

30-day price · 6059-15.00 (-4.2%)
Low$341.00High$365.00Close$342.00As of21 May, 00:00 UTC
Profile
CompanyUchiyama Holdings Co Ltd
Ticker6059.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Uchiyama Holdings Co Ltd operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92.

Uchiyama Holdings Co Ltd has a liquidity position that is currently medium, with a current ratio of 1.62, indicating the company can cover its short-term liabilities with its short-term assets. The company holds JPY 10,758,237,000 in cash and equivalents, but this is offset by long-term debt of JPY 13,637,708,000, resulting in a negative net cash position. This suggests the company may need to rely on operating cash flow or external financing to service its debt obligations. The company's profitability is underperforming relative to industry norms, with a return on equity (ROE) of -1.29% and a return on assets (ROA) of -0.51%. These negative returns indicate that the company is not generating sufficient returns to cover its cost of capital, which is a concern for investors. The operating loss of JPY 294,567,000 and net loss of JPY 158,982,000 further underscore the company's financial challenges. Uchiyama Holdings Co Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to sector-specific risks, such as regulatory changes or shifts in demand for biotechnology services. The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The operating cash flow of JPY 2,002,765,000 is a positive sign, but it is not sufficient to offset the net loss or the capital expenditure of JPY 896,404,000. The company's capital structure is heavily leveraged, with a debt-to-equity ratio of 1.1, which increases financial risk and may limit its ability to invest in growth opportunities. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position is a key flag, suggesting potential liquidity constraints. However, the low dilution risk implies that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders. The company's recent financial performance and capital structure suggest that it may need to manage its debt more effectively to improve its financial health. Recent events, including the company's financial performance and capital structure, have been disclosed in its latest financial statements. The company's operating cash flow and capital expenditure figures indicate that it is investing in its operations, but the net loss and negative ROE suggest that these investments are not yet generating returns. The company's management will need to address these issues to improve its financial performance and reduce its financial risk.
Key takeaways
  • Uchiyama Holdings Co Ltd is experiencing negative returns on equity and assets, indicating poor profitability.
  • The company has a negative net cash position, which increases liquidity risk.
  • Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
  • The company's debt-to-equity ratio is 1.1, indicating a leveraged capital structure.
  • Operating cash flow is positive but insufficient to offset the net loss and capital expenditure.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$7.27B
Gross profit$510.2M
Operating income-$294.6M
Net income-$159.0M
R&D
SG&A
D&A
SBC
Operating cash flow$2.00B
CapEx-$896.4M
Free cash flow
Total assets$31.12B
Total liabilities$18.76B
Total equity$12.37B
Cash & equivalents$10.76B
Long-term debt$13.64B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$23.80B-$1.75B-$2.23B-$3.42B
FY-3$24.96B-$505.7M-$650.0M-$1.35B
FY-2$26.91B-$812.9M-$400.6M-$2.39B
FY-1$28.84B$92.8M$213.9M-$230.6M
FY0$29.11B-$112.7M$2.05B$1.37B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$29.75B$13.67B$10.87B
FY-3$30.57B$12.89B$12.05B
FY-2$30.07B$12.26B$9.45B
FY-1$31.12B$12.37B$10.76B
FY0$31.06B$14.24B$11.62B
PeriodOCFCapExFCFSBC
FY-4-$857.3M-$1.65B-$3.42B
FY-3$1.74B-$1.24B-$1.35B
FY-2$7.3M-$2.47B-$2.39B
FY-1$2.00B-$896.4M-$230.6M
FY0$254.6M-$1.06B$1.37B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$7.27B-$294.6M-$159.0M
FQ-6$7.20B$72.2M$40.2M
FQ-5$7.30B$53.8M$282.8M
FQ-4$7.34B$134.9M$74.7M
FQ-3$7.26B-$373.7M$1.65B
FQ-2$7.33B$234.8M$191.2M
FQ-1$7.50B$206.7M$215.3M
FQ0$7.43B$57.7M$110.1M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$31.12B$12.37B$10.76B
FQ-6$32.06B$12.31B$11.13B
FQ-5$30.70B$12.59B$12.46B
FQ-4$30.61B$12.58B$12.24B
FQ-3$31.06B$14.24B$11.62B
FQ-2$30.22B$14.36B$10.13B
FQ-1$30.19B$14.61B$10.33B
FQ0$30.66B$14.58B$10.47B
PeriodOCFCapExFCFSBC
FQ-7$2.00B-$896.4M
FQ-6
FQ-5$51.7M-$869.5M
FQ-4
FQ-3$254.6M-$1.06B
FQ-2
FQ-1$563.8M-$718.2M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$12.37B
Net cash-$2.88B
Current ratio1.6
Debt/Equity1.1
ROA-0.5%
ROE-1.3%
Cash conversion-12.6%
CapEx/Revenue-12.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
Metric6059Activity
Op margin-4.1%5.6% medp25 -4.2% · p75 12.6%below median
Net margin-2.2%2.8% medp25 -3.4% · p75 8.8%below median
Gross margin7.0%36.5% medp25 23.7% · p75 65.2%bottom quartile
CapEx / revenue-12.3%-4.9% medp25 -11.5% · p75 -2.0%bottom quartile
Debt / equity110.0%69.3% medp25 7.9% · p75 120.9%above median
Observations
IR observations
Last actual EPS105.85 JPY
Last actual revenue29,105,850,000 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 01:44 UTC#96fab997
Market quoteclose JPY 355.00 · shares 0.02B diluted
no public URL
2026-05-12 01:44 UTC#f5b83714
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 01:08 UTCJob: 2749371b